Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time - PubMed (original) (raw)
Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time
Keun Ho Ryu et al. Thromb Res. 2009 Jul.
Abstract
Thrombosis and thromboembolic occlusions of major and minor blood vessels are a major complication in various peripheral vascular diseases. Antiplatelet agents (APA), key tools in the treatment of atherothrombosis, therefore became a mainstay medication for a wide range of vascular diseases. Cilostazol and Ginkgo biloba extract (GB), commonly used remedies for peripheral arterial disease, inhibit platelet aggregation with distinct therapeutic mechanisms. In this study, we have investigated if GB can potentiate the antiplatelet effects of cilostazol to explore the utility of combination therapy of cilostazol and GB against peripheral occlusive vascular diseases. GB or cilostazol was evaluated alone or in combination for the antiplatelet activity using in vitro and in vivo models. In addition, potential bleeding side effect of the combinative therapy was assessed by measuring bleeding time, prothrombin time (PT) and activated partial thromboplastin time (aPTT) in vivo after oral administration. In in vitro assays using freshly isolated human platelets, the combination of cilostazol and GB showed superior inhibition of both the shear and the collagen-induced platelet aggregation to those of each drug alone. In accordance with these enhanced in vitro antiplatelet activities, the combinative therapy showed enhanced anti-thrombotic effects in in vivo pulmonary embolism model and arterial thrombosis model. In particular, the increase of survival rate in pulmonary embolism model by combination treatment of cilostazol (25 mg/kg) and GB (20 mg/kg) was higher more than two-fold of those of the respective drugs. Notably, the combination of cilostazol and GB did not show a significant effect on the bleeding time, PT and aPTT increase, suggesting that GB may potentiate the antiplatelet effect of cilostazol without the prolongation of bleeding time or coagulation time. With these studies, we suggest that combinative therapy of GB and cilostazol might offer enhanced anti-thrombotic efficacies without increasing side-effects.
Similar articles
- Pharmacodynamic interaction studies of Ginkgo biloba with cilostazol and clopidogrel in healthy human subjects.
Aruna D, Naidu MU. Aruna D, et al. Br J Clin Pharmacol. 2007 Mar;63(3):333-8. doi: 10.1111/j.1365-2125.2006.02759.x. Epub 2006 Sep 29. Br J Clin Pharmacol. 2007. PMID: 17010102 Free PMC article. Clinical Trial. - Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding.
Goto S. Goto S. Atheroscler Suppl. 2005 Dec 15;6(4):3-11. doi: 10.1016/j.atherosclerosissup.2005.09.002. Epub 2005 Nov 4. Atheroscler Suppl. 2005. PMID: 16275169 Review. - Antiplatelet and antithrombotic activities of methanol extract of Usnea longissima.
Lee KA, Kim MS. Lee KA, et al. Phytother Res. 2005 Dec;19(12):1061-4. doi: 10.1002/ptr.1791. Phytother Res. 2005. PMID: 16372374 - Antiplatelet and antithrombotic activity of cilostazol is potentiated by dipyridamole in rabbits and dissociated from bleeding time prolongation.
Li H, Cone J, Fong M, Kambayashi J, Yoshitake M, Liu Y. Li H, et al. Cardiovasc Drugs Ther. 2005 Jan;19(1):41-8. doi: 10.1007/s10557-005-6896-0. Cardiovasc Drugs Ther. 2005. PMID: 15883755 - Antiplatelet drugs: a review of their pharmacology and management in the perioperative period.
Hall R, Mazer CD. Hall R, et al. Anesth Analg. 2011 Feb;112(2):292-318. doi: 10.1213/ANE.0b013e318203f38d. Epub 2011 Jan 6. Anesth Analg. 2011. PMID: 21212258 Review.
Cited by
- Ginkgo biloba and risk of cancer: secondary analysis of the Ginkgo Evaluation of Memory (GEM) Study.
Biggs ML, Sorkin BC, Nahin RL, Kuller LH, Fitzpatrick AL. Biggs ML, et al. Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):694-8. doi: 10.1002/pds.1979. Pharmacoepidemiol Drug Saf. 2010. PMID: 20582906 Free PMC article. Clinical Trial. - Antiplatelet, Antithrombotic, and Fibrinolytic Activities of Campomanesia xanthocarpa.
Klafke JZ, Arnoldi da Silva M, Fortes Rossato M, Trevisan G, Banderó Walker CI, Martins Leal CA, Olschowsky Borges D, Chitolina Schetinger MR, Noal Moresco R, Medeiros Frescura Duarte MM, Soares Dos Santos AR, Nazário Viecili PR, Ferreira J. Klafke JZ, et al. Evid Based Complement Alternat Med. 2012;2012:954748. doi: 10.1155/2012/954748. Epub 2011 Sep 7. Evid Based Complement Alternat Med. 2012. PMID: 21915188 Free PMC article. - Antiplatelet effects of qishen yiqi dropping pill in platelets aggregation in hyperlipidemic rabbits.
Wang Y, Wang J, Guo L, Gao X. Wang Y, et al. Evid Based Complement Alternat Med. 2012;2012:205451. doi: 10.1155/2012/205451. Epub 2012 Aug 27. Evid Based Complement Alternat Med. 2012. PMID: 22969824 Free PMC article. - Rodent models of pulmonary embolism and chronic thromboembolic pulmonary hypertension.
Karpov AA, Vaulina DD, Smirnov SS, Moiseeva OM, Galagudza MM. Karpov AA, et al. Heliyon. 2022 Feb 24;8(3):e09014. doi: 10.1016/j.heliyon.2022.e09014. eCollection 2022 Mar. Heliyon. 2022. PMID: 35295664 Free PMC article. Review. - UPLC-Q-TOF/MS-Based Plasma Metabolomics to Evaluate the Effects of Aspirin Eugenol Ester on Blood Stasis in Rats.
Shen D, Ma N, Yang Y, Liu X, Qin Z, Li S, Jiao Z, Kong X, Li J. Shen D, et al. Molecules. 2019 Jun 27;24(13):2380. doi: 10.3390/molecules24132380. Molecules. 2019. PMID: 31252591 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical